share_log

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

《每日生物技术脉搏》:Neurocrine、Editas 候选人的美国食品药品管理局孤儿药标签;BridgeBio 的 PRV 的出售;PolarityTE 产品的 RMAT 认证
Benzinga Real-time News ·  2022/05/13 10:43
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去24小时生物技术领域的热门发展综述:
Stocks In Focus
关注的股票
Switzerland Approves Moderna's COVID-19 Shot For Kids 6-11
瑞士批准Moderna为6-11岁儿童拍摄新冠肺炎
The Swiss drug regulatory authority has approved Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine for children ages 6-11. 
瑞士药品监管机构已经批准了。Moderna中国(纳斯达克:信使)6-11岁儿童新冠肺炎疫苗
The approval is for the vaccine's two-dose series of 50 micrograms per dose, Moderna added.
Moderna补充说,批准的是该疫苗的两剂系列,每剂50微克。
Shares were up 6.72% at $138.92 Friday. 
该公司股价上周五上涨6.72%,至138.92美元。
Neurocrine's Huntington's Candidate Secures FDA Orphan Drug Tag
Neurocrine的亨廷顿候选人获得FDA孤儿药物标签
The FDA has granted Orphan Drug Designation to Neurocrine Biosciences Inc's (NASDAQ:NBIX) valbenazine for Huntington's disease (HD). 
美国食品和药物管理局已将孤儿药物名称授予美国Neurocrine Biosciences Inc.纳斯达克:nbix)valbenazine治疗亨廷顿病(HD)。
The treatment of chorea associated with...
与HD相关的...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发